Delivery Order SPE2DB25D3201-SPE2DB26FNNME
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) under a firm fixed price contract valued at $1,390.76. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by June 20, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) under a firm fixed-price contract valued at $1,690.56. The order was competitively awarded without set-aside designation and is scheduled for completion by September 10, 2025. AmerisourceBergen will fulfill this pharmaceutical delivery from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mesalamine DR 1.2 GM tablets (120-count supply) on September 18, 2025, with a ceiling value of $8,208.17 and an ultimate completion date of September 19, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $3,199.95. The award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mesalamine DR 1.2 GM tablets (120 count) under a firm fixed-price contract valued at $3,925.16. The order was competitively awarded without set-aside designation and carries an ultimate completion date of September 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a continuation of the company's role...
- The Defense Logistics Agency awarded a delivery order valued at $1,577.50 to AmerisourceBergen Drug Corp for Mesalamine DR 1.2 GM tablets (120 count) on September 10, 2025, with an ultimate completion date of September 11, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at the awardee's Conshohocken, Pennsylvania location, which serves as the company's corporate headquarters and primary distribution hub...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mesalamine DR 1.2 GM tablets (120 count) on August 29, 2025, with a ceiling value of $1,419.34 and completion deadline of September 2, 2025. This firm fixed-price delivery order was awarded without set-aside restrictions through open competition. The order will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,781.36 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count packages) with a completion date of June 2, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 16, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $10,411.70. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 17, 2025. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and...
- The Defense Logistics Agency awarded a delivery order valued at $1,615.86 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units). This firm fixed-price delivery order, issued on May 15, 2025, represents a competitive award with no set-aside designation and is scheduled for completion by May 16, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB26FNNMEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $1,881.25. The award was competitively procured with no set-aside designation and is scheduled for completion by October 22, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a leading pharmaceutical distributor serving federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. This comprehensive pharmaceutical prime vendor contract enables the company to supply a broad range of medications, vaccines, medical devices, and healthcare commodities to support military and federal healthcare programs globally. The DLA has established this vehicle to provide flexible access to critical pharmaceutical products across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 10/21/25 |